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Alzheimer's disease (AD), the most common form of neurode-
generative senile dementia, is associated with selective loss of
cholinergic neurons and reduced level of acetylcholine neuro-
transmitter. It is characterized by memory deﬁcit and progressive
impairment of cognitive functions1. AD affects millions of elderly
people, and the number of patients is expected to increase in the
next 20 years. Many factors have been found to be implicated in
AD, such as low levels of acetylcholine, β-amyloid deposits,
oxidative damage and metal ions, which seem to play signiﬁcant
roles in the disease2. Current treatment of AD focuses on
increasing cholinergic neurotransmission in the brain by inhibiting
cholinesterases (ChEs) with medicines including tacrine, donepe-
zil, rivastigmine and galantamine3. Unfortunately, the potential
effectiveness offered by the above inhibitors is often limited by
their side effects. For example, clinical studies have shown that
tacrine has hepatotoxic liability4. Due to the multi-pathogenesis of
AD, one of the current strategies is to develop novel anti-AD
agents with multiple potencies5.
Genistein is biosynthetically the simplest isoﬂavonoid compound
of the Leguminosae6. It expresses a wide range of biological
activities, such as antioxidant, anti-cancer and antimicrobial7–9.
In recent years, it was reported that genistein showed neuroprotec-
tive effect and ameliorated learning and memory deﬁcits in the AD
rat model10,11. Besides, a number of genistein derivatives have
been reported as anti-AD agents in the past years (Fig. 1)12,13. These
results indicate that genistein could be used as leading compound
for the treatment of AD.
Polyamines are aliphatic molecules with amine groups distributed
along their structures14. They have always been the concern of
medicinal chemists as a universal template15. Our group has been
involved in the development of polyamine conjugates as potential
drugs for many years16–19. It was found that quinoline-polyamine
conjugates exhibited potent ChEs inhibition activity and poly-
amine occupied the gorge of AChE20. Therefore, in the present
study, in order to enhance the pharmacological potential of
genistein, a series of genistein conjugates modiﬁed with polyamine
were designed, synthesized as anti-Alzheimer agents.Figure 1 Chemical structures of ge2. Results and discussion
2.1. Synthesis of target compounds 4a–4h
The synthetic routes to target compounds are summarized in
Scheme 1. The starting material genistein 1 was treated with ethyl
2-chloroacetate in acetone to give intermediate 2, which was heated
with K2CO3 in water and then mixed with HCl yielding compound 3.
Then compound 3 converted to the intermediates by reaction with
amines or Boc protected polyamines in DMF. At last, the Boc groups
subsequently were removed using HCl (4 mol/L) at room tempera-
ture, producing target compounds 4a–4h as hydrochloride salts. All
the structures of the target compounds were conﬁrmed by 1H NMR,
ESI-MS and elemental analysis.2.2. Enzyme inhibition assays
All the newly synthesized compounds (4a–4h) were screened
against AChE and BChE in vitro according to the modiﬁed Ellman
method. Rivastigmine was used as control. The ChEs inhibition
results were listed as the inhibition ratio at a tested concentration
of 50 mmol/L (Table 1). We also tested the IC50 value of compounds
4b and 4h (Table 2).
The results showed that all of the target compounds possessed
ChEs inhibition activity, and compound 4b exhibited the strongest
inhibition to AChE with an IC50 value of 2.75 μmol/L which was
better than rivastigmine (5.60 μmol/L), compound 4h also showed
good activity with IC50 values of 46.59 μmol/L. Genistein, the
parent molecule, inhibited the AChE activity to less than 50% at
the concentration of 100 μmol/L (Table 2). It indicated that
conjugation polyamines with genistein could increase the inhibi-
tion activity of AChE. Besides, it seemed that AChE inhibitory
potency of conjugates was closely related to the length and the end
group of the polyamine chain. Compounds (4b–4d) modiﬁed by
diamine were more active than compounds conjugated with
monoamine or triamine.
In the assay of BChE inhibtion studies, compound 4h showed
the most potent inhibition for BChE with an inhibition rate ofnistein and genistein derivatives.
Table 1 Inhibitory activity of target compounds for AChE and BChE.
Compound R X Inhibition ratios for AChEa (%) Inhibition ratios for BChEa (%)
4a 0 7.8873.58 1.1970.59
4b 1 90.4071.23 26.0572.52
4c 1 37.0272.07 13.7771.05
4d 1 34.4972.76 9.0270.23
4e 2 19.2871.87 11.7270.82
4f 2 10.1970.44 9.5271.48
4g 2 16.5471.36 17.8872.83
4h 2 51.0470.55 39.2075.64
Rivastigmine – – 86.4570.71 94.6073.19
aInhibition ratios for AChE and BChE in the presence of 50 μmol/L compound (mean7SEM of two experiments), AChE from Electric Eel, BChE
from equine serum.
Scheme 1 Reaction conditions and reagents: (a) ethyl 2-chloroacetate, K2CO3, I2, acetone, reﬂux, 6 h; (b) DMSO, K2CO3, H2O, 85 1C, 10 h;
(c) 10% HCl, rt, overnight; (d) EDC, NHS, amines, DMF, rt, overnight; (e) 4 mol/L HCl, EtOH, rt, overnight.
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showed quite weaker inhibitory effect than AChE. The result
indicated that these genistein derivatives might favor the binding
to AChE, which was in agreement with the literature reported12.2.3. Kinetic characterization of AChE inhibition
The inhibition type of AChE was investigated by graphical
analysis of steady state inhibition data (Fig. 2A) using compound
4b as a typical example. The Lineweaver–Burk plots describing 4b
inhibition showed both increasing slopes and increasing intercepts
with higher inhibitor concentration, indicating a mixed-type
inhibition. These results revealed that compound 4b bounded to
both the catalytic active site (CAS) and the peripheral anionic site
(PAS) of AChE, which is also in agreement with the results of our
molecular modeling studies.2.4. Molecular modeling
To investigate the interaction mode of compound 4b with TcAChE
(protein data bank (PDB) code:1ZGB) molecular modeling was
carried out by AUTODOCK 4.0 package with PyMOL program
(Fig. 2B)21,22. The docking result demonstrated that compound 4b
exhibited multiple binding modes with AChE. In the 4b-TcAChE
complex, compound 4b occupied the entire enzymatic CAS, mid-
gorge and PAS. The charged nitrogen made a cation–π interaction
with the Trp84. At the midgorge recognition site, the chromone
moiety displayed classic π–π stacking with the phenyl ring of
Try334, with the ring-to-ring distance being 4.4 Å and 4.7 Å,
respectively. At the PAS, the benzene of genistein moiety stacked
against the Trp279 through π–π interaction with the distance of
4.4 Å. The result showed that compound 4b was able to bind both
CAS and PAS of AChE which was in agreement with the result of
kinetic study.
Figure 2 Lineweaver–Burk plots (A) and the docking model (B) for compound 4b with TcAChE.
Table 2 IC50 of some target compounds for AChE
and BChE.
Compound IC50 AChE
a (μmol/L) IC50 BChEa (μmol/L)
4b 2.7570.28 450
4h 46.5973.87 450
Genistein 4100 4100
Rivastigmine 5.6071.50 1.6570.05
aIC50 (μmol/L), 50% inhibitory concentration (mean7SEM of
three experiments) of AChE or BChE.
Figure 3 UV–Vis spectrum of compound 4b (20 μmol/L) alone or in
the presence of 20 μmol/L Fe3þ, Cu2þ and Zn2þ.
Table 3 MTT assay of HepG-2 cell viability.
Compound Inhibition ratiosa (%)
4a 6.40
4b 1.53
4c 14.57
4d 1.17
4e 8.51
4f 11.74
4g 16.72
4h 16.30
Tacrine 57.35
aInhibition ratios for HepG-2 cell viability in the presence of
10 μmol/L compound, each sample is the mean of three indepen-
dent experiments.
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The abnormally high levels of biometals in affected areas of the
brain catalyze the formation of reactive oxygen species, which
further aggravates oxidative stress contributing to β-amyloid
formation. These effects have rendered metal chelators as very
promising drugs for AD. Thus, the chelation abilities of compound
4b towards biometal Fe3þ, Cu2þ and Zn2þ in water were studied
by UV-Vis spectrometry. The results in Fig. 3 shows that the
absorbance spectra of 4b exhibited an apparent increase after the
addition of Fe3þ or Zn2þ, and a red-shift in the maximum
absorption from 259 nm to 268 nm occurred. This result indicated
that there was an interaction between compound 4b and Fe3þ or
Zn2þ ion due to complex formation24. However, slight changeswere observed in the UV spectrum of 4b after adding Cu2þ,
indicating the poor chelating ability of compound 4b for Cu2þ ion.
2.6. MTT assay of cell viability
The toxicity of synthesized compounds was determined in HepG-2.
Results indicated that the most potent two inhibitors, 4b and 4h,
showed no obvious effect on cell viability at concentration of
10 μmol/L, as shown in Table 3. Compared with tacrine, they had
lower toxicity on cell viability.3. Conclusions
In conclusion, a series of novel genistein–polyamine conjugates
(4a–4h) were designed, synthesized and evaluated for cholinester-
ase inhibition, metal-chelating activity and human hepatoma
cell viability. Results indicated that these compounds had sig-
niﬁcant ChEs inhibitory activity. Compound 4b exhibited the
strongest inhibition to AChE with an IC50 value of 2.75 μmol/L.
Lineweaver–Burk plot and molecular modeling study showed that
compound 4b targeted both the CAS and PAS of AChE. Besides,
compound 4b showed potent metal chelating ability. In addition,
these compounds showed low cytotoxicity by MTT assay in vitro.
Compound 4b may be considered to be a novel multi-functional
low-toxic drug candidate for the treatment of AD.
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4.1. Materials
Acetylcholinesterase (AChE, E.C. 3.1.1.7, from Electric Eel),
butyrylcholinesterase (BChE, E.C. 3.1.1.8, from equine serum),
5,50-dithiobis-(2-nitrobenzoic acid) (DTNB), butyrylthiocholine
chloride (BTC), and acetylthiocholine chloride (ATC) were
purchased from Sigma-Aldrich and rivastigmine hydrochloride
standard was purchased from Sunve Pharmaceutical Co., Ltd.
(Shanghai, China). 1H NMR spectra were recorded using TMS as
the internal standard in DMSO or D2O with a Bruker AV-400
spectrometer at 400 MHz. MS spectra were recorded on a
Shimadzu LCMS-2010A instrument with an ESI mass selective
detector. Elemental analyses were performed on a Gmbe VarioEL
Elemental Instrument. Flash column chromatography was per-
formed with silica gel (200–300 mesh) purchased from Qingdao
Haiyang Chemical Co., Ltd.4.2. Chemistry
4.2.1. Synthesis of intermediate 2
Genistein (2.70 g, 10 mmol), ethyl 2-chloroacetate (1.47 g, 12 mmol),
anhydrous K2CO3 (0.69 g, 5 mmol) and catalytic amount KI (0.05 g)
were added in anhydrous acetone (100 mL), and the mixture was
reﬂuxed for 6 h. The solution was ﬁltered and the ﬁlter cake was
recrystallized from EtOH to give light yellow solid 2.60 g; Yield 73%;
MS (ESI) m/z 357.1 [MþH]þ.4.2.2. Synthesis of intermediate 3
Compound 2 (0.71 g, 2 mmol), 5% Na2CO3 and DMSO (40 mL)
were heated at 85 1C for 10 h. Then the reaction mixture was
poured into 10% HCl (300 mL), kept overnight and ﬁltered. The
ﬁlter cake was recrystallized from EtOH to give light brown solid
0.46 g; Yield 70%.4.2.3. Synthesis of target compounds 4a–4h
Compound 3 (0.36 g, 1 mmol), 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide (EDC, 0.29 g, 1.5 mmol) and N-hydroxysucci-
nimide (NHS, 0.17 g, 1.5 mmol) were stirred at room temperature
for 1.5 h, and then amines or Boc protected amines (1.2 mmol)
were added. The mixture was stirred at room temperature over-
night. Then the solvent was poured into water and extracted with
ethyl acetate (20 mL 3). The solution was dried over anhydrous
Na2SO4 and concentrated. The intermediates were puriﬁed by ﬂash
chromatography with chloroform/methanol/ammonia (20:1:0.5, v/v/v)
elution.
The intermediates were dissolved in EtOH (10 mL) and stirred
at 0 1C for 10 min. Then 4 mol/L HCl (diluted with EtOH) was
added dropwise at 0 1C. The reaction mixture was stirred at room
temperature overnight. The solution typically gave a white solid
precipitate. The precipitate was collected and washed several times
with absolute ethanol and ether, and dried under vacuum to give
pure target compounds 4a–4h.
N-butyl-2-(5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-
7-yloxy)acetamide (4a): White solid; m.p. 180–183 1C; Yield
63%. 1H NMR (400 MHz, DMSO-d6): δ 12.95 (s, 1H), 9.63 (s,
1H), 8.43 (s, 1H), 8.16 (s, 1H), 7.44–7.36 (m, 2H), 6.87–6.79 (m,
2H), 6.66 (d, J¼2.3 Hz, 1H), 6.45 (d, J¼2.3 Hz, 1H), 4.61
(s, 2H), 3.13 (dd, 2H, J¼13.0, 6.8 Hz), 1.46–1.37 (m, 2H), 1.26(dd, J¼15.1, 7.5 Hz), 0.86 (t, J¼7.3 Hz). ESI-MS m/z: 384.4
[MþH]þ. Anal. Calcd. for C21H21NO6  0.1C2H5OH: C, 65.52;
H, 5.76; N, 3.60, Found C, 65.44; H, 5.82; N, 3.43.
N-(2-(dimethylamino)ethyl)-2-(5-hydroxy-3-(4-hydroxyphenyl)-
4-oxo-4H-chromen-7-yloxy)acetamide hydrochloride (4b): White
solid; m.p. 143–145 1C; Yield 49%. 1H NMR (400 MHz, D2O): δ
7.99–7.89 (m, 1H), 7.22 (s, 2H), 6.81 (s, 2H), 6.41–6.34 (m, 1H),
6.22 (s, 1H), 4.36 (s, 2H), 3.52 (s, 2H), 3.19 (s, 2H), 2.58 (s, 6H).
ESI-MS m/z: 399.4 [MþH-HCl]þ. Anal. Calcd. for C21H21N2O6 
HCl  0.4H2O: C, 57.05; H, 5.43; N, 6.34, Found C, 57.03; H, 5.52;
N, 6.73.
N-(3-aminopropyl)-2-(5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-
chromen-7-yloxy)acetamide hydrochloride (4c): White solid; m.p.
187–189 1C; Yield 50%. 1H NMR (400 MHz, D2O): δ 7.98 (s, 1H),
7.27 (d, 2H, J¼8.5 Hz), 6.87 (d, 2H, J¼8.4 Hz), 6.38 (s, 1H), 6.23
(d, 1H, J¼2.0 Hz), 4.31 (s, 2H), 3.30 (t, 2H, J¼6.8 Hz), 3.00–2.93
(m, 2H), 1.90–1.82 (m, 2H). ESI-MS m/z: 385.4 [MþH-HCl]þ.
Anal. Calcd. for C20H20N2O6 HCl  3.5H2O: C, 49.64; H, 5.83; N,
5.79, Found C, 49.69; H, 5.60; N, 5.58.
N-(4-aminobutyl)-2-(5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-
chromen-7-yloxy)acetamide hydrochloride (4d): White solid; m.p.
214–216 1C; Yield 48%: 1H NMR (400 MHz, D2O): δ 7.83
(s, 1H), 7.14 (s, 2H), 6.76 (d, 2H, J¼7.9 Hz), 6.21 (s, 1H), 6.08
(s, 1H), 4.14 (s, 2H), 3.12 (t, 2H, J¼6.8 Hz), 2.95–2.85 (m, 2H),
1.50 (dd, 4H, J¼31.9, 7.1 Hz). ESI-MS m/z: 399.4 [MþH-HCl]þ.
Anal. Calcd. for C21H22N2O6 HCl  2.5H2O: C, 52.56; H, 5.88; N,
5.84, Found C, 52.64; H, 5.51; N, 5.57.
2-(5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yloxy)-N-
(4-(piperazin-1-yl)butyl)acetamide hydrochloride (4e): White solid;
m.p. 215–217 1C; Yield 46%: 1H NMR (400 MHz, D2O): δ 7.95
(s, 1H), 7.23 (d, 2H, J¼8.4 Hz), 6.81 (d, 2H, J¼8.5 Hz), 6.36
(s, 1H), 6.19 (s, 1H), 4.30 (s, 2H), 3.47 (s, 8H), 3.14 (dd, 4H,
J¼14.9, 7.6 Hz), 1.62 (s, 2H), 1.50–1.40 (m, 2H). ESI-MS m/z:
468.5 [MþH-2HCl]þ. Anal. Calcd. for C25H29N3O6  2HCl  0.4H2O:
C, 54.83; H, 5.85; N, 7.67, Found C, 54.49; H, 5.78; N, 7.63.
N-(3-(3-aminopropylamino)propyl)-2-(5-hydroxy-3-(4-hydroxy-
phenyl)-4-oxo-4H-chromen-7-yloxy)acetamide hydrochloride (4f):
White solid; m.p. 147–149 1C; Yield 37%: 1H NMR (400 MHz,
D2O): δ 7.96 (s, 1H), 7.24 (d, 2H, J¼7.8 Hz), 6.82 (d, 2H,
J¼8.0 Hz), 6.37 (s, 1H), 6.20 (s, 1H), 4.31 (s, 2H), 3.24 (t, 2H,
J¼6.6 Hz), 3.06–2.92 (m, 6H), 1.97 (dt, J¼15.8, 7.9 Hz), 1.86–
1.77 (m, 2H). ESI-MS m/z: 442.5 [MþH-2HCl]þ. Anal. Calcd. for
C23H27N3O6  2HCl  1.2H2O: C, 51.54; H, 5.90; N, 7.84, Found C,
51.86; H, 5.92; N, 7.45.
N-(4-(3-aminopropylamino)butyl)-2-(5-hydroxy-3-(4-hydroxy-
phenyl)-4-oxo-4H-chromen-7-yloxy)acetamide hydrochloride (4g):
QWhite solid; m.p. 176–178 1C; Yield 35%: 1H NMR (400 MHz,
D2O): δ 7.86 (s, 1H), 7.15 (d, 2H, J¼8.6 Hz), 6.74 (d, 2H,
J¼8.6 Hz), 6.23 (d, 1H, J¼2.0 Hz), 6.08 (d, 1H, J¼2.2 Hz,),
4.13 (s, 2H), 3.08 (t, 2H, J¼6.9 Hz), 3.01–2.90 (m, 6H), 1.92
(dd, 2H, J¼10.5, 5.3 Hz), 1.52 (d, 2H, J¼6.3 Hz), 1.45–1.37
(m, 2H). ESI-MS m/z: 456.5 [MþH-2HCl]þ. Anal. Calcd. for
C24H29N3O6  2HCl  4H2O: C, 48.00; H, 6.55; N, 7.00, Found C,
48.01; H, 6.81; N, 7.38.
N-(4-(4-aminobutylamino)butyl)-2-(5-hydroxy-3-(4-hydroxyphenyl)-
4-oxo-4H-chromen-7-yloxy)acetamide hydrochloride (4h): White
solid; m.p. 187–189 1C; Yield 37%: 1H NMR (400 MHz, D2O):
δ 7.62 (s, 1H), 7.04 (d, 2H), 6.71 (d, 2H, J¼7.8 Hz),
5.97 (s, 2H), 3.98 (s, 2H), 3.13 (s, 2H), 3.04–2.95 (m, 6H), 1.72
(s, 4H), 1.63 (s, 2H), 1.49 (d, 2H, J¼7.0 Hz). ESI-MS m/z: 470.5
[MþH-2HCl]þ. Anal. Calcd. for C25H31N3O6  2HCl  2.5H2O: C,
51.11; H, 6.52; N, 7.15, Found C, 51.03; H, 6.29; N, 6.93.
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All the assays were under 0.1 mol/L KH2PO4/K2HPO4 buffer, pH
8.0, using a Shimadzu 2450 Spectrophotometer. Enzyme solutions
were prepared to give 2.0 units/mL in 2 mL aliquots. The assay
medium contained phosphate buffer (pH 8.0), 50 mL of 0.01 mol/L
DTNB, 10 mL of enzyme, and 50 mL of 0.01 mol/L substrate
(ATC). The substrate was added to the assay medium which
contained enzyme, buffer and DTNB with inhibitor (0, 5, 10, 20,
35, and 50 mmol/L) after 15 min of incubation time. The activity
was determined by measuring the increase in absorbance at
412 nm at 1 min intervals at 37 1C. Calculations were performed
according to the method of the equation in Ellman et al.23. The in
vitro BChE assay used the similar method described above. The
concentration of compound that effected 50% inhibition of ChEs
activities (IC50) was calculated by nonlinear regression of the
inhibition ratio–concentration curve, using Origin 7.5 program.4.4. Kinetic characterization of AChE inhibition
Kinetic characterization of AChE was performed using a reported
method. Six different concentrations of substrate were mixed in the
1 mL 0.1 mol/L KH2PO4/K2HPO4 buffer (pH 8.0), containing
50 mL of DTNB, 10 mL AChE and 50 mL substrate. Test com-
pound was added into the assay solution and pre-incubated with
the enzyme at 37 1C for 15 min, followed by the addition of
substrate. Kinetic characterization of the hydrolysis of ATC
catalyzed by AChE was done spectrometrically at 412 nm. A
parallel control with no inhibitor in the mixture, allowed adjusting
activities to be measured at various times.4.5. Molecular modeling
The crystal structure of the torpedo AChE (code ID: 1ZGB) was
obtained in the PDB after eliminating the inhibitor and water
molecules. The 3D structure of compound 4b was prepared as
similar as previously described20.
Docking studies were carried out using the AUTODOCK 4.0
program using ADT. The enzyme structure was used as an input
for the AUTOGRID program. AUTOGRID performed a precalcu-
lated atomic afﬁnity grid maps for each atom type in the ligand
plus an electrostatics map and a separate desolvation map present
in the substrate molecule. All maps were calculated with 0.375 Å
spacing between grid points. The center of the grid box was placed
at the bottom of the active site gorge (AChE [2.781 64.383
67.971]). The dimensions of the active site box were set at
50 Å 46 Å 46 Å.
Flexible ligand docking was performed for the compounds.
Docking calculations were carried out using the Lamarckian
genetic algorithm (LGA) and all parameters were the same for
each docking.4.6. Metal-chelating study
The chelating studies were made in water using a UV-Vis
spectrophotometer (SHIMADZC UV-2450PC). The absorption
spectrum of compound 4b (20 μmol/L), alone or in the presence
of FeCl3, CuSO4 or ZnCl2 (20 μmol/L), was recorded with wave-
length ranging from 200 to 500 nm after incubating for 30 min at
room temperature. The ﬁnal volume of reaction mixture was 1 mL,and the ﬁnal concentrations of tested compound and metals were
20 mmol/L.
4.7. MTT assay of HepG-2 cell viability
Cells were cultured at 37 1C under a 5% CO2 atmosphere. The
antiproliferative ability of compounds was evaluated in HepG-2
cells by the conversion of MTT to a purple formazan precipitate
as previously described19. Cells were seeded into 96-well plates
at 5 103 cells/well. After 12 h, 10 μmol/L of compounds was
subsequently added and incubated for 48 h. The inhibition rate was
calculated from plotted results using untreated cells as 100%.
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